Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro

Journal article

Open access

Peer reviewed

R.S. Herbst, E.B. Garon, D.-W. Kim, B. Chul Cho, J.L. Pérez Gracia, J.-Y. Han, C. Dubos Arvis, M. Majem, M. Forster, I. Monnet, …

Annals of oncology, v 29, pp x42-x43

Dec 2018

Files and links (1)

url

https://doi.org/10.1093/annonc/mdy511.003View

Published, Version of Record (VoR) Open

2 Record Views

Title: Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro
Creators: R.S. Herbst - Yale University
E.B. Garon - University of California, Los Angeles
D.-W. Kim - Seoul National University Hospital
B. Chul Cho - Yonsei University
J.L. Pérez Gracia - Clinica Universidad de Navarra
J.-Y. Han - National Cancer Center
C. Dubos Arvis - Centre François Baclesse
M. Majem - Hospital de Sant Pau
M. Forster - University College Hospital
I. Monnet - Hôpital Intercommunal de Créteil
S. Novello - Ospedale San Luigi Gonzaga
Z. Szalai - Petz Aladár Megyei Oktató Kórház
M.A. Gubens - University of California, San Francisco
W.-C. Su - National Cheng Kung University Hospital
G.L. Ceresoli - Humanitas Gavazzeni
A. Samkari - Merck & Co., Inc., Rahway, NJ, USA (United States)
E. Jensen - Merck & Co., Inc., Rahway, NJ, USA (United States)
G.M. Lubiniecki - Merck & Co., Inc., Rahway, NJ, USA (United States)
P. Baas - The Netherlands Cancer Institute
Publication Details: Annals of oncology, v 29, pp x42-x43
Publisher: Elsevier
Resource Type: Journal article
Language: English
Academic Unit: Pediatrics
Other Identifier: 991021838715704721